Two MS Drug Candidates Show Promise Repairing Nerve Damage

For the first time in multiple sclerosis research history, two drug candidates have successfully repaired damaged nerve insulation in disease models.

Tapani Koppinen from the University of Helsinki discovered the breakthrough molecules during his doctoral research. Every previous attempt to develop a remyelination drug for MS has failed, making these findings particularly significant for the three million people worldwide living with the disease.

Multiple sclerosis occurs when the immune system attacks myelin, the protective coating around nerve fibers that allows electrical signals to travel efficiently through the brain and spinal cord. Current treatments can slow the immune attack, but none repair damage that has already occurred.

That gap hits hardest in progressive MS, where injury accumulates over years and existing treatments do little to help. The brain naturally tries to regrow myelin after damage, but in MS patients, this repair capacity breaks down as the disease advances.

Koppinen's team took two completely different approaches. The first molecule blocks an overactive stress response inside brain cells that prevents repair cells from doing their job. The second changes the composition of scar tissue that physically blocks nerve repair, allowing the healing process to proceed.

Both molecules successfully crossed the blood-brain barrier in laboratory animals, solving one of the biggest technical challenges for brain-targeted drugs. Both reduced inflammation and increased myelin regrowth in MS disease models, despite working through entirely separate mechanisms.

The Bright Side

These findings represent the furthest any remyelination candidate has progressed in MS research. While previous attempts have stalled at earlier stages, both molecules showed consistent results across different testing approaches.

The research appeared in two separate publications in fall 2025, with the stress-blocking molecule featured in Molecular Therapy and the scar-targeting compound in Neuropharmacology. Associate Professor Merja Voutilainen's research group continues developing both candidates.

The next step involves moving toward human clinical trials. Koppinen notes the molecules can also help researchers better understand what blocks repair in MS tissue, potentially opening new pathways for treatment development.

No MS patient currently has access to a treatment that reverses damage from their disease. These molecules haven't changed that reality yet, but they've moved closer than any previous candidate, offering genuine hope where dozens of attempts have fallen short.